Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected adults~* CD4 count \> 250 cells/mm3~* Not presently receiving HIV antiretroviral therapy (\> 6 months or naïve)~* Viral load \> 3000 RNA copies/mL (3.5 log)~* No planned HIV anti-retroviral therapy for 8 weeks~Exclusion Criteria:~* Prior retinal eye disease~* CD4 \< 250 cells/µL~* Renal failure~* Active malignancy~* Corticosteroid therapy~* Age \< 18 or \> 65 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Chloroquine (Type: EXPERIMENTAL): Chloroquine 205mg or 500mg orally once daily (Results pooled)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).